The increased expression of inflammatory markers in NAFLD patients may promote thrombopoietin development, resulting in larger platelets in the bone marrow and platelet activation, which in turn causes liver damage, and creates a vicious cycle. Here, THPO is linked to metabolic dysfunction-associated steatotic liver disease.